Is new hope on the horizon for obesity?

The Lancet

Volumn 372, Issue 9653, 2008, Pages 1859-1860

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; DEXAMPHETAMINE; FENFLURAMINE; FLUOXETINE; PHENTERMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG;

ARTICLE; BODY FAT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET; DRUG MECHANISM; HEALTH CARE PERSONNEL; HUMAN; HYPERTENSION; MONOTHERAPY; OBESITY; PREVALENCE; PRIORITY JOURNAL; PULSE RATE; QUALITY OF LIFE; SIDE EFFECT; UNITED STATES; WEIGHT REDUCTION;

EID: 56649111290     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61792-4     Document Type: Note

References (12)

1. CDC. State-specific prevalence of obesity among adults: United States, 2007. MMWR Morb Mortal Wkly Rep 57 (2008) 765-768
2. Astrup A., Madsbad S., Breum L., Jensen T.J., Kroustrup J.P., and Larsen T.M. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1906-1913
3. Simons-Morton D.G., Obarzanek E., and Cutler J.A. Obesity research-limitations of methods, measurements, and medications. JAMA 295 (2006) 826-828
4. Haddock C.R., Poston W.S.C., Dill P.L., Foreyt J.P., and Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 26 (2002) 262-273
5. Rucker D., Padwal R., Li S.K., Curioni C., and Lau D.C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335 (2007) 1194-1199
6. Weintraub M., Sundaresan P.R., Madan M., et al. Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 51 (1992) 586-594
7. Bray G.A., and Greenway F.L. Current and potential drugs for treatment of obesity. Endocr Rev 20 (1999) 805-875
8. Bray G.A., and Greenway F.L. Pharmacological treatment of the overweight patients. Pharmacol Rev 59 (2007) 151-173
9. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
10. Nissen S.E., Nicholls S.J., Wolski K., et al., for the STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560
11. Bray G.A. The battle of the bulge (2007), Dorrance Publishing, Pittsburgh, PA
12. European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia (Oct 23, 2008). http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf (accessed Oct 29, 2008).